Retrospective study finds upadacitinib improves lung function in inflammatory myopathy-related interstitial lung disease, suggesting a viable treatment option.
UPA significantly improved lung function, reduced glucocorticoid dependence, and suppressed systemic inflammation in refractory IIM-ILD with acceptable safety, supporting its use as a promising therapeutic option in IIM-ILD patients after conventional treatment failure.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: